Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025)
Telix Pharmaceuticals (TLX) posted Non-Current Deferred Tax Liability of $44.7 million for Q4 2025, up 628.73% on a QoQ basis from $6.1 million in Q4 2024, and up 628.73% year-over-year from $6.1 million in Q4 2024.
Telix Pharmaceuticals (TLX) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $44.7 million in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 628.73% year-over-year to $44.7 million; the TTM figure through Dec 2025 stood at $44.7 million (up 628.73% YoY), while the FY2025 annual figure was $44.7 million, up 671.33% from the prior year.
- Non-Current Deferred Tax Liability improved to $44.7 million in Q4 2025, from $6.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $44.7 million in Q4 2025 and bottomed at $6.1 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Telix Pharmaceuticals | 4.52 Bn | 4.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2024 | 6.13 Mn |
| Dec 31, 2024 | 6.13 Mn |